ViCentra Announces Commercial Launch of New Smartphone-Controlled Kaleido Automated Insulin Delivery Patch Pump System

ViCentra has announced the commercial launch of its Kaleido automated insulin delivery system, which integrates the company’s patch pump with Diabeloop’s DBLG2 algorithm and Dexcom G7 Continuous Glucose Monitoring (CGM). The system allows users to control insulin delivery directly from their smartphones, eliminating the need for a separate dedicated device. Kaleido, the smallest and lightest insulin patch pump in its class, is designed to be discreet and intuitive, offering greater flexibility for diabetes management. The new system streamlines hybrid closed-loop therapy by combining Kaleido’s design with Dexcom G7’s all-in-one sensor and transmitter, enhancing convenience. ViCentra plans to roll out commercial deliveries in Germany and the Netherlands later this summer, following a pilot launch in the Netherlands. The system will be formally unveiled at the 60th DDG Diabetes Congress in Berlin from May 13–15, 2026. ViCentra’s Chief Executive Officer, Tom Arnold, stated that the launch marks an important milestone, making automated insulin delivery simpler and more accessible. Users can begin therapy with Kaleido using Diabeloop’s DBLG1 algorithm and transition smoothly to the DBLG2 and Dexcom G7 system later this summer. The company has expanded its operations in Europe and is preparing for future growth in the U.S. ViCentra will exhibit at the DDG Congress, engaging with healthcare professionals and stakeholders. The company’s mission is to improve diabetes management through innovation, simplicity, and design excellence. Further updates on availability and transition pathways will be provided as the launch approaches.